Search results
Results from the WOW.Com Content Network
The screening glucose challenge test (sometimes called the O'Sullivan test) is performed between 24 and 28 weeks, and can be seen as a simplified version of the oral glucose tolerance test (OGTT). No previous fasting is required for this screening test, [53] in contrast to the OGTT. The O'Sullivan test involves drinking a solution containing 50 ...
The glucose tolerance test was first described in 1923 by Jerome W. Conn. [4]The test was based on the previous work in 1913 by A. T. B. Jacobson in determining that carbohydrate ingestion results in blood glucose fluctuations, [5] and the premise (named the Staub-Traugott Phenomenon after its first observers H. Staub in 1921 and K. Traugott in 1922) that a normal patient fed glucose will ...
Disposition index is used as a measure of beta cell function and the ability of the body to dispose of a glucose load. Thus a lowering of disposition index predicts the conversion of insulin resistance to diabetes mellitus type 2. [13]
This page was last edited on 21 March 2005, at 19:07 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. [3] [4] Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. [6]
[4] [5] The immune system of the human body is different in the body of a pregnant person, compared to any other human being. Pregnant people are more susceptible to disease, and the idea of even treating these diseases can be risky. Complications caused by treating these diseases can lead to long term damage to the parent, fetus, or both.
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. [1] [2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.